Results 11 to 20 of about 64,289 (299)

Effect of intraperitoneal chemotherapy concentration on morbidity and survival [PDF]

BJS Open, 2020
Background Selected patients with colorectal peritoneal metastases are treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
F. M. K. Elekonawo, W. J. vanEden, W. Y. van derPlas, R. S. G. Ewalds, L. A. W. deJong, A. J. A. Bremers, P. H. J. Hemmer, N. F. M. Kok, S. Kruijff, A. G. J. Aalbers, P. R. deReuver   +10 more
doaj   +2 more sources

Peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy [PDF]

Journal of Coloproctology, 2018
Introduction: To evaluate the combined treatment with cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from colorectal cancer, pseudomyxoma peritonei and mesothelioma.
Bernardo Hanan, Leonardo Maciel Fonseca, Magda Maria Profeta da Luz, Antônio Lacerda-Filho, Mônica Maria Demas Álvares Cabral, Rodrigo Gomes da Silva   +5 more
doaj   +4 more sources

Efficacy and safety of intraperitoneal chemotherapy for pancreatic cancer [PDF]

BMC Surgery
Pancreatic cancer is a highly aggressive cancer with unfavorable prognosis despite the therapeutic interventions. Intraperitoneal chemotherapy has recently shown potential outcomes in the presence of peritoneal metastases.
Dorsa Safari, Mohammad Fakhrolmobasheri, Saeed Soleymanjahi   +2 more
doaj   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer [PDF]

Diagnostics, 2020
Hyperthermic intraperitoneal chemotherapy (HIPEC) in conjunction with cytoreductive surgery (CRS) holds promise as an adjunctive treatment strategy in malignancies affecting the peritoneal surface, effectively targeting remaining microscopic residual ...
McKayla J. Riggs, Prakash K. Pandalai, Joseph Kim, Charles S. Dietrich   +3 more
doaj   +2 more sources

Adjuvant Bidirectional Chemotherapy Using an Intraperitoneal Port [PDF]

Gastroenterology Research and Practice, 2012
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been established as treatment options for patients with peritoneal metastases or peritoneal mesothelioma.
Paul H. Sugarbaker, Lana Bijelic
doaj   +2 more sources

Anesthetic implications in hyperthermic intraperitoneal chemotherapy [PDF]

Journal of Anaesthesiology Clinical Pharmacology, 2019
Patients with peritoneal carcinomatosis were considered incurable with dismal survival rates till hyperthermic intraperitoneal chemotherapy after optimal cytoreductive surgery evolved. Perioperative management for these procedures is complex and involves
Nishkarsh Gupta, Vinod Kumar, Rakesh Garg, Sachidanand Jee Bharti, Seema Mishra, Sushma Bhatnagar   +5 more
doaj   +2 more sources

Effect of hyperthermia on improving neutrophil restoration after intraperitoneal chemotherapy [PDF]

International Journal of Hyperthermia, 2019
Purpose: Intraperitoneal (IP) chemotherapy has several benefits but also can have severe hematologic side effects. We compared the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) and conventional IP chemotherapy on bone marrow suppression ...
Wan-Chun Huang, Chao-Chih Wu, Yun-Ting Hsu, Chih-Long Chang   +3 more
doaj   +2 more sources

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy plus Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Malignant Ascites [PDF]

Journal of Medical Sciences
Background Patients with gastric cancer (GC) and malignant ascites (MA) usually have poor outcomes and a high risk of recurrence and mortality, even after curative gastrectomy or chemotherapy.
Hsing-Wei Yu, Guo-Shiou Liao, Ting-Ying Lee, De-Chuan Chan   +3 more
doaj   +2 more sources

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies [PDF]

, 2023
Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier ...
Creemers, G.J., Bins, S., Mathijssen, R.H.J., Lagarde, S.M., Mathijssen, Ron H.J., Wijnhoven, Bas P.L., Verhoef, C., Madsen, E.V.E., Guchelaar, N.A.D., Mostert, Bianca, Luyer, M., Creemers, Geert Jan, Koolen, Stijn L.W., Brandt-Kerkhof, A.R.M., Mathijssen, Ron H.J.; id_orcid, Brandt-Kerkhof, Alexandra R.M., van Meerten, E., Verhoef, Cornelis, Burger, Jacobus W.A., de Hingh, Ignace H.J.T., van Meerten, Esther, Koolen, S.L.W., Luyer, Misha, Burger, J.W.A., Wijnhoven, B.P.L., de Hingh, I.H.J.T., Noordman, Bo J., Noordman, B.J., Guchelaar, Niels A.D., Lagarde, Sjoerd M., Mostert, B., Madsen, Eva V.E., Bins, Sander, Madsen, Eva V.E.; id_orcid   +33 more
core   +1 more source

A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy. [PDF]

Drugs
Peritoneal metastases (PM), frequently observed in malignancies such as ovarian, colorectal, pancreatic, and gastric cancers, present a significant therapeutic challenge due to poor prognosis and limited effectiveness to systemic chemotherapy.
Rietveld PCS, Guchelaar NAD, Sassen SDT, Koch BCP, Mathijssen RHJ, Koolen SLW.   +5 more
europepmc   +3 more sources